Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
Media Release Copenhagen, Denmark, June 6, 2022 Interim results of tisotumab vedotin plus pembrolizumab from…